Identifying targets in the hunt for effective respiratory syncytial virus interventions

Expert Review of Respiratory Medicine

Volumn 6, Issue 2, 2012, Pages 215-222

  Tayyari, Farnoosh ^a   Hegele, Richard G ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

prophylaxis; respiratory syncytial virus infection; targeted therapy; treatment

Indexed keywords

ANTIVIRUS AGENT; CHEMOKINE RECEPTOR CX3CR1; HOST FACTOR; M PROTEIN; MOTAVIZUMAB; NUCLEOLIN; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RIBAVIRIN; TMC 353121; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS RNA;

ANTIVIRAL THERAPY; BRONCHIOLITIS; CELL SURFACE; DISEASE SEVERITY; DRUG CONTRAINDICATION; HOST CELL; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INCIDENCE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); POINT MUTATION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; RNA INTERFERENCE; RNA SYNTHESIS; VIRION; VIRUS ATTACHMENT; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN;

EID: 84859186367     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.12.8     Document Type: Review

References (60)

1. Nair H, Nokes DJ, Gessner BD et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375(9725), 1545-1555 (2010).
2. Walsh EE. Respiratory syncytial virus infection in adults. Semin. Respir. Crit. Care Med. 32(4), 423-432 (2011).
3. Morris JA, Blount RE, Savage RE. Recovery of cytopathogenic agent from chimpanzees with coryza. Proc. Soc. Exp. Med. 92(3), 544-549 (1956).
4. Shadman KA, Wald ER. A review of palivizumab and emerging therapies for respiratory syncytial virus. Expert Opin. Biol. Ther. 11(11), 1455-1467 (2011).
5. Collins PL, Melero JA. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus. Res. 162(1-2), 80-99 (2011).
6. Rodriguez WJ, Hall CB, Welliver R et al. Efficacy and safety of aerosolized ribavirin in young children hospitalized with influenza: a double-blind, multicenter, placebo-controlled trial. J. Pediatr. 125(1), 129-135 (1994).
7. Lagos R, DeVincenzo JP, Muñoz A et al. Safety and anti-viral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSVinfected children. Pediatr. Infect. Dis. J. 28(9), 835-837 (2009).
8. Utokaparch S, Marchant D, Gosselink JV et al. The relationship between respiratory viral loads and diagnosis in children presenting to a pediatric hospital emergency department. Pediatr. Infect. Dis. J. 30(2), e18-e23 (2011).
9. Krilov LR. Respiratory syncytial virus disease: update on treatment and prevention. Expert Rev. Anti. Infect. Ther. 9(1), 27-32 (2011).
10. Prince GA, Mathews A, Curtis SJ, Porter DD. Treatment of respiratory syncytial virus bronchiolitis and pneumonia in a cotton rat model with systemically administered monoclonal antibody (palivizumab) and glucocorticosteroid. J. Infect. Dis. 182(5), 1326-1330 (2000).
11. Kim HW, Canchola JG, Brandt CD et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89(4), 422-434 (1969).
12. Young D. FDA: MedImmune's rezield has 3x allergic reactions as synagis. BioWorld Today 21(104), 1-5 (2010).
13. American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis. Diagnosis and management of bronchiolitis. Pediatrics 118(4), 1774-1793 (2006).
14. Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK. Broadspectrum anti-viral activity of Virazole: 1-b-d-ribofuranosyl-1,2,4- triazole-3- carboxamide. Science 177(50), 705-706 (1972).
15. Olszewska W, Openshaw P. Emerging drugs for respiratory syncytial virus infection. Expert Opin. Emerg. Drugs 14(2), 207-217 (2009).
16. Olszewska W, Ispas G, Schnoeller C et al. Anti-viral and lung protective activity of a novel respiratory syncytial virus fusion inhibitor in a mouse model. Eur. Respir. J. 38(2), 401-408 (2011).
17. DeVincenzo J, Lambkin-Williams R, Wilkinson T et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc. Natl Acad. Sci. USA 107(19), 8800-8805 (2010).
18. Zamora MR, Budev M, Rolfe M et al. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am. J. Respir. Crit. Care Med. 183(4), 531-538 (2011).
19. Chapman J, Abbott E, Alber DG et al. RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrob. Agents Chemother. 51(9), 3346-3353 (2007).
20. Adams O, Bonze L, Kovacevic A, Mayatepek E, Hoehn T, Vogel M. Palivizumab-resistant human respiratory syncytial virus infection in infancy. Clin. Infect. Dis. 51(2), 185-188 (2010).
21. Radhakrishnan A, Yeo D, Brown G et al. Protein analysis of purified respiratory syncytial virus particles reveals an important role for heat shock protein 90 in virus particle assembly. Mol. Cell Proteomics 9(9), 1829-1848 (2010).
22. Hallak LK, Spillmann D, Collins PL, Peeples ME. Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection. J. Virol. 74(22), 10508-10513 (2000).
23. Techaarpornkul S, Collins PL, Peeples ME. Respiratory syncytial virus with the fusion protein as its only viral glycoprotein is less dependent on cellular glycosaminoglycans for attachment than complete virus. Virology 294(2), 296-304 (2002).
24. Teng MN, Whitehead SS, Collins PL. Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. Virology 289(2), 283-296 (2011).
25. Tiwari V, Liu J, Valyi-Nagy T, Shukla D. Anti-heparan sulfate peptides that block herpes simplex virus infection in vivo. J. Biol. Chem. 286(28), 25406-25415 (2011).
26. Behera AK, Matsuse H, Kumar M, Kong X, Lockey RF, Mohapatra SS. Blocking intercellular adhesion molecule-1 on human epithelial cells decreases respiratory syncytial virus infection. Biochem. Biophys. Res. Commun. 280(1), 188-195 (2011).
27. Pastey MK, Crowe JE, Graham BS. RhoA interacts with the fusion glycoprotein of respiratory syncytial virus and facilitates virus-induced syncytium formation. J. Virol. 73(9), 7262-7270 (1999).
28. Tripp RA, Jones LP, Haynes LM, Zheng H, Murphy PM, Anderson LJ. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat. Immunol. 2(8), 732-738 (2001).
29. Haynes LM, Moore DD, Kurt-Jones EA, Finberg RW, Anderson LJ, Tripp RA. Involvement of Toll-like receptor 4 in innate immunity to respiratory syncytial virus. J. Virol. 75(22), 10730-10737 (2001).
30. Malhotra R, Ward M, Bright H et al. Isolation and characterisation of potential respiratory syncytial virus receptor(s) on epithelial cells. Microbes Infect. 5(2), 123-133 (2003).
31. Flint SJ, Enquist LW, Krug RM, Racaniello VR, Skalka AM. Virus attachment to host cell. In: Principles of Virology: Molecular Biology, Pathogenesis and Control. ASM Press, Washington DC, DC, USA, 101-131 (2000).
32. Tayyari F, Marchant D, Moraes TJ, Duan W, Mastrangelo P, Hegele RG. Identification of nucleolin as a cellular receptor for human respiratory syncytial virus. Nat. Med. 17(9), 1132-1135 (2011).
33. Tufaro F. Virus entry: two receptors are better than one. Trends Microbiol. 5(7), 257-258 (1997).
34. Leistner CM, Gruen-Bernhard S, Glebe D. Role of glycosaminoglycans for binding and infection of hepatitis B virus. Cell Microbiol. 10(1), 122-133 (2008).
35. Said EA, Krust B, Nisole S, Svab J, Briand JP, Hovanessian AG. The anti-HIV cytokine midkine binds the cell surface-expressed nucleolin as a low affinity receptor. J. Biol. Chem. 277(40), 37492-37502 (2002).
36. Said EA, Courty J, Svab J, Delbé J, Krust B, Hovanessian AG. Pleiotrophin inhibits HIV infection by binding the cell surface-expressed nucleolin. FEBS J. 272(18), 4646-4659 (2005).
37. Nisole S, Said EA, Mische C et al. The anti-HIV pentameric pseudopeptide HB- 19 binds the C-terminal end of nucleolin and prevents anchorage of virus particles in the plasma membrane of target cells. J. Biol. Chem. 277(23), 20877-20886 (2002).
38. Budge PJ, Graham BS. Inhibition of respiratory syncytial virus by RhoA-derived peptides: implications for the development of improved anti-viral agents targeting heparin-binding viruses. J. Antimicrob. Chemother. 54(2), 299-302 (2004).
39. McLellan JS, Yang Y, Graham BS, Kwong PD. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J. Virol. 85(15), 7788-7796 (2011).
40. Bermingham A, Collins PL. The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription. Proc. Natl Acad. Sci. USA 96(20), 11259-11264 (1999).
41. Karron RA, Wright PF, Belshe RB et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J. Infect. Dis. 191(7), 1093-1104 (2005).
42. Teng MN, Whitehead SS, Bermingham A et al. Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees. J. Virol. 74(19), 9317-9321 (2000).
43. Zhang L, Peeples ME, Boucher RC, Collins PL, Pickles RJ. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J. Virol. 76(11), 5654-5666 (2002).
44. Brock SC, Goldenring JR, Crowe JE. Apical recycling systems regulate directional budding of respiratory syncytial virus from polarized epithelial cells. Proc. Natl Acad. Sci. USA 100(25), 15143-15148 (2003).
45. Teng MN, Collins PL. Identification of the respiratory syncytial virus proteins required for formation and passage of helper-dependent infectious particles. J. Virol. 72(7), 5707-5716 (1998).
46. Money VA, McPhee HK, Mosely JA, Sanderson JM, Yeo RP. Surface features of a Mononegavirales matrix protein indicate sites of membrane interaction. Proc. Natl Acad. Sci. USA 106(11), 4441-4446 (2009).
47. Dessen A, Volchkov V, Dolnik O, Klenk HD, Weissenhorn W. Crystal structure of the matrix protein VP40 from Ebola virus. EMBO J. 19(16), 4228-4236 (2000).
48. Yin R, Ding Z, Liu X, Mu L, Cong Y, Stoeger T. Inhibition of Newcastle disease virus replication by RNA interference targeting the matrix protein gene in chicken embryo fibroblasts. J. Virol. Methods 167(1), 107-111 (2010).
49. Yeo DS, Chan R, Brown G et al. Evidence that selective changes in the lipid composition of raft-membranes occur during respiratory syncytial virus infection. Virology 386(1), 168-182 (2009).
50. Robinzon S, Dafa-Berger A, Dyer MD et al. Impaired cholesterol biosynthesis in a neuronal cell line persistently infected with measles virus. J. Virol. 83(11), 5495-5504 (2009).
51. Kallewaard NL, Bowen AL, Crowe JE. Cooperativity of actin and microtubule elements during replication of respiratory syncytial virus. Virology 331(1), 73-81 (2005).
52. Mastronarde JG, Monick MM, Mukaida N, Matsushima K, Hunninghake GW. Activator protein-1 is the preferred transcription factor for cooperative interaction with nuclear factor-kB in respiratory syncytial virus-induced interleukin-8 gene expression in airway epithelium. J. Infect. Dis. 177(5), 1275-1281 (1998).
53. Fiedler MA, Wernke-Dollries K, Stark JM. Inhibition of viral replication reverses respiratory syncytial virus-induced NF-kB activation and interleukin-8 gene expression in A549 cells J. Virol. 70(12), 9079-9082 (1996).
54. Boggild AK, Krudsood S, Patel SN et al. Use of peroxisome proliferator-activated receptor g agonists as adjunctive treatment for Plasmodium falciparum malaria: a randomized, double-blind, placebo-controlled trial. Clin. Infect. Dis. 49(6), 841-849 (2009).
55. Monick M, Staber J, Thomas K et al. Respiratory syncytial virus infection results in activation of multiple protein kinase C isoforms leading to activation of mitogen-activated protein kinase. J. Immunol. 166(4), 2681-2687 (2001).
56. Marchant D, Singhera GK, Utokaparch S et al. Toll-like receptor 4-mediated activation of p38 mitogen-activated protein kinase is a determinant of respiratory virus entry and tropism. J. Virol. 84(21), 11359-11373 (2010).
57. Marchant D, Sall A, Si X et al. ERK MAP kinase-activated Arf6 trafficking directs coxsackievirus Type B3 into an unproductive compartment during virus host-cell entry. J. Gen. Virol. 90(4), 854-862 (2009).
58. Lindquist ME, Lifland AW, Utley TJ, Santangelo PJ, Crowe JE. Respiratory syncytial virus induces host RNA stress granules to facilitate viral replication. J. Virol. 84(23), 12274-12284 (2010).
59. Kauvar LM, Harcourt JL, Haynes LM, Tripp RA. Therapeutic targeting of respiratory syncytial virus G-protein. Immunotherapy 2(5), 655-661 (2010).
60. Hennessy EJ, Parker AE, O'Neill LA. Targeting Toll-like receptors: emerging therapeutics? Nat. Rev. Drug Discov. 9(4), 293-307 (2010).